Claritin 20

Claritin 20

The Claritin® family of products provides proven allergy relief from symptoms such as runny, itchy nose, sneezing, itchy, watery eyes and itchy throat that lasts all day- without causing drowsiness. Claritin is an antihistamine used to treat the symptoms of allergies, such as sneezing, watery eyes, and runny nose. Learn about side effects, interactions and indications. Claritin (loratadine) is a non-drowsy antihistamine widely used for seasonal allergies. It offers 24‑hour symptom relief with once‑daily dosing and minimal CNS effects for most users. Loratadine (Claritin) is an antihistamine. It works by blocking histamine. Histamine is a natural chemical in your body that causes allergy symptoms like itchy eyes, a runny nose, and sneezing. By blocking histamine, this medication helps relieve allergy symptoms. Detailed dosage guidelines and administration information for Claritin (loratadine). Includes dose adjustments, warnings and precautions. Claritin is the 1 doctor recommended non-drowsy oral allergy brand. When your symptoms start, doctors recommend taking non-drowsy Claritin every day of your allergy season for continuous relief (1). Claritin® offers non-drowsy relief for adults and kids from indoor and outdoor allergy symptoms. Explore Claritin® products and resources for allergy relief. Claritin provides relief of symptoms that can be triggered by over 200 different allergens. Claritin is an antihistamine, so it hinders the cascade triggered by allergens. Discover how Claritin can help manage your allergy symptoms with fewer side effects like drowsiness. This article explores its uses, effectiveness, and how it compares to other antihistamines. Loratadine is used to treat allergy symptoms, including runny or stuffy nose, sneezing, watery eyes, and itching of the eyes, nose or throat. This medicine is available as an over-the-counter (OTC) product. This product is available in the following dosage forms.

Leave a Reply

Your email address will not be published. Required fields are marked *

*
*